Therapeutics in Huntington's Disease (Q39252195)

10 September 2017

title

Therapeutics in Huntington's Disease (English)

1 reference

10 September 2017

0 references

Annie Killoran

1

1 reference

10 September 2017

Kevin M Biglan

series ordinal

2

1 reference

10 September 2017

publication date

8 February 2012

1 reference

Current treatment options in neurology

10 September 2017

published in

1 reference

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Symptomatic treatment of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

The current clinical management of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Huntington's disease: from molecular pathogenesis to clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Role of tetrabenazine for Huntington's disease-associated chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Olanzapine for Huntington's disease: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Effectiveness of risperidone in Huntington chorea patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Paroxetine retards disease onset and progression in Huntingtin mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Effects of rivastigmine on motor and cognitive impairment in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Two years' follow-up of rivastigmine treatment in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

The Use of Methylphenidate for Cognitive Decline Associated with HIV Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Improvements in Executive Function Correlate with Enhanced Performance and Functioning and Health-Related Quality of Life: Evidence from 2 Large, Double-Blind, Randomized, Placebo-Controlled Trials in ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Bruxism in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Bilateral human fetal striatal transplantation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Gene therapy in mouse models of huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic — Rigid form

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Efficacy of levetiracetam in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11940-012-0165-X

Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements

21 January 2018

1 reference

12 December 2020

Clonazepam in the treatment of choreiform activity

1 reference

12 December 2020

Short-term effects of olanzapine in Huntington disease.

1 reference

12 December 2020

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

12 December 2020

10.1007/S11940-012-0165-X

Identifiers

DOI

1 reference

release_rocw5zrfevd73og2jxixpzgt7i

10 September 2017

Fatcat ID

0 references

1 reference